Recombinant Human IFN-alpha B2/IFNA8 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11018-IF

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11018-IF-010
11018-IF-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

P32881.1

Conjugate

Unconjugated

Applications

Bioactivity

View all IFN-alpha B2/IFNA8 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived IFN-alpha B2/IFNA8 protein
Cys24-Glu189

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Cys24

Predicted Molecular Mass

19 kDa

SDS-PAGE

23-27 kDa, under reducing conditions.

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129.
The ED50 for this effect is 1.20-12.0 pg/mL.

Scientific Data Images for Recombinant Human IFN-alpha B2/IFNA8 Protein, CF

Recombinant Human IFN-alpha B2/IFNA8 Protein Bioactivity.

Recombinant Human IFN-alpha B2/IFNA8 Protein (Catalog # 11018-IF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 1.20-12.0 pg/mL

Recombinant Human IFN-alpha B2/IFNA8 Protein SDS-PAGE.

2 μg/lane of Recombinant Human IFN-alpha B2/IFNA8 Protein (Catalog # 11018-IF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 23-27 kDa.

Formulation, Preparation and Storage

11018-IF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha B2/IFNA8

Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2-4). Structurally, type I IFNs belong to the class of five helical-bundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds (5). The extracellular domain (ECD) of mature human IFNA8, also known as IFN-alpha B2, shares 60% aa sequence identity with mouse homolog. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha-subunit) and IFNAR2 (beta -subunit) (6, 7). Individual IFNA subtypes are known to display unique efficacies to viral protection, and IFNA8 is the most potent IFNA, judging by both antiviral and antiproliferative activities (8). The reason for this higher potency is unstructured tail region of IFNA8 that gains structure during complex formation and might explain the differences in activity between IFNAs (8). IFNA8 has been shown to exhibit antiproliferative and cytotoxic effects on renal cancer cell (RCC) lines and chronic myelogenous leukemia (CML)-derived cell lines (9, 10).

References

  1. Pestka, S. et al. (1987) Annu. Rev. Biochem. 56:727.
  2. Goeddel, D.V. et al. (1980) Nature 287:411.
  3. Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
  4. Schreiber, G. and J. Piehler (2015) Trends Immunol. 36:139.
  5. Wittling, M.C. et al. (2021) Front Immunol. 11:605673.
  6. van Pesch, V. et al. (2004) J. Virol. 78:8219.
  7. James, C.M. et al. (2007) Vaccine. 25(10):1856.
  8. Slutzki, M. et al. (2006) J Mol Biol. 360:1019.
  9. Yanai, Y. et al. (2002) Cancer Letter 185:173.
  10. Yanai, Y. et al. (2001) J. Interferon Cytokine Res 21:1129.

Long Name

Interferon alpha 8

Alternate Names

IFN-alpha B2, IFNA8, IFNalpha B2

Entrez Gene IDs

3445 (Human)

Gene Symbol

IFNA8

UniProt

P32881.1

Additional IFN-alpha B2/IFNA8 Products

Product Documents for Recombinant Human IFN-alpha B2/IFNA8 Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human IFN-alpha B2/IFNA8 Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.